Rapport Therapeutics
NEWS
Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts.
See our latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
Rapport Therapeutics, a clinical-stage biotech aiming to develop precision medicines for neurological disorders, launched Tuesday with $100 million in Series A financing.
IN THE PRESS